TGFB1 and neoplasm: Galunisertib, a small molecule inhibitor of TGFβ receptor I (TGFβRI) [171], has been shown to inhibition of TGFβ-mediated immune-suppression decreasing tumor growth and bone metastasis [172,173,174,175].